An exploratory analysis of the efficacy of ocrelizumab in patients with multiple sclerosis with increased disability.
Jerry S WolinskyNatalie J EngmannJinglan PeiAshish PradhanClyde MarkowitzEdward J FoxPublished in: Multiple sclerosis journal - experimental, translational and clinical (2020)
In patients with increased baseline disability, ocrelizumab reduced the risk of confirmed disability progression versus interferon β-1a in patients with relapsing-onset MS and versus placebo in patients with progression-onset MS.